CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations
CollPlant Biotechnologies (NASDAQ:CLGN) has appointed Bowman Bagley as Vice President, Commercial North America in a newly created position. Bagley, who previously served as VP at Wasatch Biolabs and CEO at Advanced BioMatrix, will lead the company's commercial strategy and execution in North America.
The appointment aligns with CollPlant's growth strategy for its non-animal-derived recombinant human collagen (rhCollagen) technology. Bagley will oversee sales, marketing, logistics, and market expansion for CollPlant's rhCollagen-based products and platforms, particularly focusing on bioinks portfolio growth and research market sales.
Bagley brings extensive experience in collagen-based biomaterials, 3D bioprinting, and tissue engineering, along with a track record in sales, product development, and licensing. He holds a B.S. in Neuroscience and an MBA from the University of Utah.
CollPlant Biotechnologies (NASDAQ:CLGN) ha nominato Bowman Bagley Vice Presidente Commerciale per il Nord America, in una posizione di nuova creazione. Bagley, che in precedenza è stato VP presso Wasatch Biolabs e CEO di Advanced BioMatrix, guiderà la strategia commerciale e la sua esecuzione in Nord America.
La nomina è in linea con la strategia di crescita di CollPlant per la sua tecnologia di collagene umano ricombinante (rhCollagen) non derivato da animali. Bagley supervisionerà vendite, marketing, logistica ed espansione del mercato per i prodotti e le piattaforme basate su rhCollagen di CollPlant, con un focus particolare sulla crescita del portafoglio bioink e sulle vendite nel mercato della ricerca.
Bagley porta con sé una vasta esperienza nei biomateriali a base di collagene, nella biostampa 3D e nell'ingegneria tissutale, oltre a una comprovata esperienza in vendite, sviluppo prodotto e licensing. È laureato in Neuroscienze e ha conseguito un MBA presso l'Università dello Utah.
CollPlant Biotechnologies (NASDAQ:CLGN) ha nombrado a Bowman Bagley como Vicepresidente Comercial para Norteamérica, en un puesto recién creado. Bagley, quien anteriormente se desempeñó como VP en Wasatch Biolabs y CEO en Advanced BioMatrix, liderará la estrategia comercial y su ejecución en Norteamérica.
El nombramiento está alineado con la estrategia de crecimiento de CollPlant para su tecnología de colágeno humano recombinante (rhCollagen) no derivado de animales. Bagley supervisará ventas, marketing, logística y expansión de mercado para los productos y plataformas basados en rhCollagen de CollPlant, enfocándose especialmente en el crecimiento del portafolio de bioinks y las ventas en el mercado de investigación.
Bagley aporta una amplia experiencia en biomateriales basados en colágeno, bioimpresión 3D e ingeniería de tejidos, junto con un historial en ventas, desarrollo de productos y licencias. Posee una licenciatura en Neurociencia y un MBA de la Universidad de Utah.
CollPlant Biotechnologies (NASDAQ:CLGN)는 새로 신설된 북미 상업 부문 부사장에 보우먼 배글리를 임명했습니다. 이전에 Wasatch Biolabs의 부사장과 Advanced BioMatrix의 CEO를 역임한 배글리는 북미 지역에서 회사의 상업 전략 및 실행을 이끌게 됩니다.
이번 임명은 동물 유래가 아닌 재조합 인간 콜라겐(rhCollagen) 기술에 대한 CollPlant의 성장 전략과 일치합니다. 배글리는 CollPlant의 rhCollagen 기반 제품 및 플랫폼의 판매, 마케팅, 물류 및 시장 확장을 총괄하며, 특히 바이오잉크 포트폴리오 성장과 연구 시장 판매에 중점을 둘 예정입니다.
배글리는 콜라겐 기반 생체재료, 3D 바이오프린팅, 조직 공학 분야에서 풍부한 경험을 보유하고 있으며, 판매, 제품 개발 및 라이선싱 분야에서도 뛰어난 실적을 가지고 있습니다. 그는 유타 대학교에서 신경과학 학사와 MBA 학위를 받았습니다.
CollPlant Biotechnologies (NASDAQ:CLGN) a nommé Bowman Bagley au poste de Vice-Président Commercial pour l'Amérique du Nord, un poste nouvellement créé. Bagley, qui a précédemment occupé les fonctions de VP chez Wasatch Biolabs et de CEO chez Advanced BioMatrix, dirigera la stratégie commerciale et son exécution en Amérique du Nord.
Cette nomination s'aligne avec la stratégie de croissance de CollPlant pour sa technologie de collagène humain recombiné (rhCollagen) non dérivé d'animaux. Bagley supervisera les ventes, le marketing, la logistique et l'expansion du marché pour les produits et plateformes basés sur le rhCollagen de CollPlant, en mettant particulièrement l'accent sur la croissance du portefeuille de bio-encres et les ventes sur le marché de la recherche.
Bagley apporte une vaste expérience dans les biomatériaux à base de collagène, l'impression 3D biologique et l'ingénierie tissulaire, ainsi qu'un solide parcours en ventes, développement produit et licences. Il est titulaire d'une licence en neurosciences et d'un MBA de l'Université de l'Utah.
CollPlant Biotechnologies (NASDAQ:CLGN) hat Bowman Bagley zum Vice President Commercial North America in einer neu geschaffenen Position ernannt. Bagley, der zuvor als VP bei Wasatch Biolabs und CEO bei Advanced BioMatrix tätig war, wird die kommerzielle Strategie und deren Umsetzung in Nordamerika leiten.
Die Ernennung steht im Einklang mit CollPlants Wachstumsstrategie für seine nicht-tierisch gewonnenen rekombinanten humanen Kollagen (rhCollagen)-Technologie. Bagley wird den Vertrieb, das Marketing, die Logistik und die Marktexpansion für CollPlants rhCollagen-basierte Produkte und Plattformen überwachen, mit besonderem Fokus auf das Wachstum des Bioinks-Portfolios und den Verkauf im Forschungsmarkt.
Bagley bringt umfangreiche Erfahrung in kollagenbasierten Biomaterialien, 3D-Bioprinting und Gewebeengineering mit sowie eine nachgewiesene Erfolgsbilanz in Vertrieb, Produktentwicklung und Lizenzierung. Er hat einen B.Sc. in Neurowissenschaften und einen MBA von der University of Utah.
- Strategic hire with deep expertise in collagen biomaterials and commercial operations
- Creation of new VP position signals commitment to North American market expansion
- Appointment strengthens commercial capabilities in bioinks and research markets
- None.
New
REHOVOT,
"We are excited to welcome Bowman to the CollPlant leadership team as we scale our commercial operations and development programs," said Yehiel Tal, Chief Executive Officer of CollPlant. "His deep expertise in collagen-based biomaterials, 3D bioprinting, and tissue engineering aligns perfectly with our growth strategy. Bowman's proven track record in sales, product development, licensing, and operational execution will be instrumental as we grow our bioinks portfolio and expand rhCollagen sales to the research market as well as to strategic collaborators in the fields of regenerative and aesthetic medicine."
Mr. Bagley joins CollPlant from Wasatch Biolabs, a genomics research company, where he served as Vice President and Fractional CxO, leading revenue operations and growth initiatives. Previously, he spent nearly a decade at Advanced BioMatrix, a global supplier of purified collagen and extracellular matrix products, where he served as Chief Executive Officer. During his tenure, he held leadership roles across product development, business development, and global sales, helping to establish the company as a leading supplier in the research and tissue engineering space.
In addition to his leadership roles, Mr. Bagley has advised life science companies on go-to-market strategies, commercial partnerships, and scaling operations. He is also an active angel investor with NuFund Venture Group, where he conducts due diligence on emerging biotech ventures.
"I am honored to join CollPlant at such an exciting time in its growth trajectory," said Bowman Bagley. "CollPlant's recombinant human collagen platform represents a transformative advancement in regenerative medicine and biomaterials. I'm eager to contribute to the company's mission and help accelerate the commercial success of its innovative product portfolio, while driving long-term value for shareholders."
Mr. Bagley holds a B.S. in Neuroscience from Brigham Young University and an MBA from the University of
About CollPlant
CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release includes forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company's preferences regarding such methods, and including its ability to conclude a non-dilutive financing transaction; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or Company's strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
+ 972-73-2325600
Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo - https://mma.prnewswire.com/media/2729980/Bowman_Bagley.jpg
Logo - https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-appoints-collagen-biomaterials-expert-as-new-head-of-north-america-commercial-operations-302504157.html
SOURCE CollPlant
FAQ
Who is CollPlant's new Vice President of Commercial North America?
What will be Bowman Bagley's role at CollPlant (NASDAQ:CLGN)?
What is Bowman Bagley's background and experience?
How does this appointment align with CollPlant's strategy?
What products does CollPlant (NASDAQ:CLGN) develop?
